Skip to main content

Peer Review reports

From: Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel

Original Submission
9 May 2022 Submitted Original manuscript
12 Jun 2022 Reviewed Reviewer Report
30 Jun 2022 Reviewed Reviewer Report
7 Jul 2022 Reviewed Reviewer Report
31 Aug 2022 Author responded Author comments - Reshma Mahtani
28 Sep 2022 Author responded Author comments - Reshma Mahtani
Resubmission - Version 2
31 Aug 2022 Submitted Manuscript version 2
11 Oct 2022 Reviewed Reviewer Report
12 Oct 2022 Reviewed Reviewer Report
25 Oct 2022 Reviewed Reviewer Report
9 Nov 2022 Author responded Author comments - Reshma Mahtani
Resubmission - Version 3
9 Nov 2022 Submitted Manuscript version 3
Publishing
16 Nov 2022 Editorially accepted
22 Dec 2022 Article published 10.1186/s12885-022-10325-9

You can find further information about peer review here.

Back to article page